Bosentan for the treatment of adult pulmonary hypertension

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Badesch DB, Champion HC, Sanchez MA et al.: Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.54(1 Suppl. S),S55–S66 (2009).
  MedlineGoogle Scholar
• 2  Galiè N, Hoeper MM, Humbert M et al.: Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J.30(20),2493–2537 (2009).▪▪ Excellent updated consensus statement on the classification, diagnosis and treatment of pulmonary hypertension.
  MedlineGoogle Scholar
• 3  Simonneau G, Robbins IM, Beghetti M et al.: Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.54(1 Suppl. 1),S43–S54 (2009).
  MedlineGoogle Scholar
• 4  Rich S, Kaufmann E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med.327(2),76–81 (1992).
  Medline CASGoogle Scholar
• 5  Sitbon O, Humbert M, Jais X et al.: Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation111(23),3105–3111 (2005).
  Medline CASGoogle Scholar
• 6  Morrell NW, Adnot S, Archer SL et al.: Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol.54(1 Suppl, 1),S20–S31 (2009).
  Medline CASGoogle Scholar
• 7  Hassoun PM, Mouthon L, Barberà JA et al.: Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol.54(1 Suppl. 1),S10–S19 (2009).
  Medline CASGoogle Scholar
• 8  McLaughlin VV, Archer SL, Badesch DB et al.: ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol.53(17),1573–1619 (2009).
  MedlineGoogle Scholar
• 9  Keogh AM, Mayer E, Benza RL et al.: Interventional and surgical modalities of treatment in pulmonary hypertension. J. Am. Coll. Cardiol.54(1 Suppl. 1),S67–S77 (2009).
  MedlineGoogle Scholar
• 10  Mereles D, Ehlken N, Kreuscher S et al.: Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation114(14),1482–1489 (2006).
  MedlineGoogle Scholar
• 11  Rich S, Seidlitz M, Dodin E et al.: The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest114(3),787–792 (1998).
  Medline CASGoogle Scholar
• 12  Fuster V, Steele PM, Edwards WD et al.: Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation70(4),580 (1984).
  Medline CASGoogle Scholar
• 13  Motte S, McEntee K, Naeije R: Endothelin receptor antagonists. Pharmacol. Ther.110(3),386–414 (2006).
  Medline CASGoogle Scholar
• 14  Davie N, Haleen SJ, Upton PD et al.: ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Crit. Care Med.165(3),398–405 (2002).
  MedlineGoogle Scholar
• 15  Clozel M, Gray GA, Breu V, Löffler B, Osterwalder R: The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem. Biophys. Res. Comm.186(2),867–873 (1992).
  Medline CASGoogle Scholar
• 16  MacLean MR, McCulloch KM, Baird M: Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J. Cardiovasc. Pharmacol.23(5),838–845 (1994).
  Medline CASGoogle Scholar
• 17  Giaid A, Yanagisawa M, Langleben D et al.: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med.328(24),1732–1739 (1993).
  Medline CASGoogle Scholar
• 18  Opitz CF, Ewert R, Kirch W, Pittrow D: Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur. Heart J.29(16),1936–1948 (2008).▪▪ Important review of dual versus selective endothelin receptor antagonism.
  Medline CASGoogle Scholar
• 19  Dupuis J, Goresky CA, Fournier A: Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J. Appl. Physiol.81(4),1510–1515 (1996).
  Medline CASGoogle Scholar
• 20  de Nucci G, Thomas R, D’Orleans-Juste P et al.: Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl Acad. Sci. USA85(24),9797–9800 (1988).
  Medline CASGoogle Scholar
• 21  Masaki T: Possible role of endothelin in endothelial regulation of vascular tone. Annu. Rev. Pharmacol. Toxicol.35(1),235–255 (1995).
  Medline CASGoogle Scholar
• 22  Takahashi H, Soma S, Muramatsu M et al.: Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery. Eur. Respir. J.18(1),5–14 (2001).
  Medline CASGoogle Scholar
• 23  Soma S, Takahashi H, Muramatsu M, Oka M, Fukuchi Y: Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats. Am. J. Respir. Cell Mol. Biol.20(4),620–630 (1999).
  Medline CASGoogle Scholar
• 24  Abraham D, Vancheeswaran R, Dashwood M et al.: Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol.151(3),831–841 (1997).
  Medline CASGoogle Scholar
• 25  Roux S, Breu V, Ertel SI, Clozel M: Endothelin antagonism with bosentan: a review of potential applications. J. Mol. Med.77(4),364–376 (1999).
  Medline CASGoogle Scholar
• 26  Kim H, Yung GL, Marsh JJ et al.: Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur. Respir. J.15(4),640 (2000).
  Medline CASGoogle Scholar
• 27  Chen SJ, Chen YF, Meng QC et al.: Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J. Appl. Physiol.79(6),2122–2131 (1995).
  Medline CASGoogle Scholar
• 28  Dingemanse J, Van Giersbergen P: Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet.43(15),1089–1115 (2004).
  Medline CASGoogle Scholar
• 29  Dhillon S, Keating GM: Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension. Am. J. Cardiovasc. Drugs9(5),331–350 (2009).▪▪ Excellent review of bosentan’s pharmacology.
  Medline CASGoogle Scholar
• 30  Dingemanse J, Bodin F, Weidekamm E, Kutz K, van Giersbergen P: Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J. Clin. Pharmacol.42(3),283–289 (2002).
  Medline CASGoogle Scholar
• 31  Weber C, Schmitt R, Birnboeck H et al.: Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J. Clin. Pharmacol.39(7),703–714 (1999).
  Medline CASGoogle Scholar
• 32  Weber C, Gasser R, Hopfgartner G: Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metabol. Disposit.27(7),810–815 (1999).
  Medline CASGoogle Scholar
• 33  Dingemanse J, van Giersbergen PLM: Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. Int. J. Clin. Pharmacol. Ther.40(7),310–316 (2002).
  Medline CASGoogle Scholar
• 34  van Giersbergen PLM, Popescu G, Bodin F, Dingemanse J: Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J. Clin. Pharmacol.43(1),15–22 (2003).
  Medline CASGoogle Scholar
• 35  Tracleer^® (bosentan). Full Prescribing Information. Actelion Pharmaceuticals US, Inc., CA, USA, August 2009.
  Google Scholar
• 36  Treiber A, Schneiter R, Häusler S, Stieger B: Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metabol. Disposit.35(8),1400–1407 (2007).
  Medline CASGoogle Scholar
• 37  van Giersbergen PLM, Halabi A, Dingemanse J: Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int. J. Clin. Pharmacol. Ther.44(3),113–118 (2006).
  Medline CASGoogle Scholar
• 38  van Giersbergen PLM, Treiber A, Schneiter R, Dietrich H, Dingemanse J: Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin. Pharmacol. Ther.81(3),414–419 (2007).
  Medline CASGoogle Scholar
• 39  Burgess G, Hoogkamer H, Collings L, Dingemanse J: Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur. J. Clin. Pharmacol.64(1),43–50 (2008).
  Medline CASGoogle Scholar
• 40  Gruenig E, Michelakis E, Vachiéry J et al.: Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J. Clin. Pharmacol.49(11),1343–1352 (2009).
  Medline CASGoogle Scholar
• 41  Galiè N, Rubin L, Hoeper M et al.: Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet371(9630),2093–2100 (2008).▪ Important randomized controlled trial reporting the benefits of bosentan in preventing disease progression in mildly symptomatic pulmonary arterial hypertension patients.
  Medline CASGoogle Scholar
• 42  Wrishko RE, Dingemanse J, Yu A et al.: Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J. Clin. Pharmacol.48(5),610–618 (2008).
  Medline CASGoogle Scholar
• 43  McRae MP, Lowe CM, Tian X et al.: Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J. Pharmacol. Exp. Ther.318(3),1068–1075 (2006).
  Medline CASGoogle Scholar
• 44  Dingemanse J, van Giersbergen PLM, Patat A, Nilsson PN: Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antivir. Ther. (Lond.).15(2),157–163 (2010).
  Medline CASGoogle Scholar
• 45  Channick RN, Simonneau G, Sitbon O et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo controlled study. Lancet358(9288),1119–1123 (2001).▪ First controlled trial to describe the clinical efficacy of oral bosentan as a pulmonary hypertension treatment (Study 351).
  Medline CASGoogle Scholar
• 46  Rubin LJ, Badesch DB, Barst RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med.346(12),896–903 (2002).▪ An early, larger, randomized controlled trial that reported the clinical efficacy of bosentan as a pulmonary hypertension therapy.
  Medline CASGoogle Scholar
• 47  Sitbon O, Badesch DB, Channick RN et al.: Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension. Chest124(1),247–254 (2003).
  Medline CASGoogle Scholar
• 48  Jing Z, Strange G, Zhu X et al.: Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension. J. Heart Lung Transplant.29(2),150–156 (2010).
  MedlineGoogle Scholar
• 49  Sohn D, Kim H, Kim M et al.: Beneficial and adverse effects of bosentan treatment in korean patients with pulmonary artery hypertension. Korean Circ. J.39(3),105–110 (2009).
  Medline CASGoogle Scholar
• 50  Provencher S, Sitbon O, Humbert M et al.: Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur. Heart J.27(5),589–595 (2006).
  Medline CASGoogle Scholar
• 51  Denton CP, Pope JE, Peter H et al.: Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann. Rheum. Dis.67(9),1222–1228 (2008).
  Medline CASGoogle Scholar
• 52  Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ: Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J. Heart Lung Transplant.26(2),181–187 (2007).
  MedlineGoogle Scholar
• 53  Humbert M, Segal ES, Kiely DG et al.: Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur. Respir. J.30(2),338–344 (2007).
  Medline CASGoogle Scholar
• 54  Galiè N, Hinderliter AL, Torbicki A et al.: Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J. Am. Coll. Cardiol.41(8),1380–1386 (2003).
  Medline CASGoogle Scholar
• 55  Barst RJ, Rubin LJ, Long WA et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N. Engl. J. Med.334(5),296–301 (1996).▪ First trial demonstrating a survival benefit with a targeted pulmonary hypertension therapy compared with conventional medical therapy.
  Medline CASGoogle Scholar
• 56  Steiner MK, Preston IR, Klinger JR et al.: Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension. Chest130(5),1471–1480 (2006).
  Medline CASGoogle Scholar
• 57  Suleman N, Frost AE: Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest126(3),808–815 (2004).
  Medline CASGoogle Scholar
• 58  Kim NH, Channick RN, Rubin LJ: Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest124(4),1612–1615 (2003).
  MedlineGoogle Scholar
• 59  Launay D, Sitbon O, Le Pavec J et al.: Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology49(3),490–500 (2010).
  Medline CASGoogle Scholar
• 60  Williams MH, Das C, Handler CE et al.: Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart92(7),926–932 (2006).
  Medline CASGoogle Scholar
• 61  Joglekar A, Tsai FS, McCloskey DA et al.: Bosentan in pulmonary arterial hypertension secondary to scleroderma. J. Rheumatol.33(1),61–68 (2006).
  Medline CASGoogle Scholar
• 62  Speich R, Jenni R, Opravil M, Pfab M, Russi EW: Primary pulmonary hypertension in HIV infection. Chest100(5),1268–1271 (1991).
  Medline CASGoogle Scholar
• 63  Opravil M, Pechère M, Speich R et al.: HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am. J. Respir. Crit. Care Med.155(3),990–995 (1997).
  Medline CASGoogle Scholar
• 64  Sitbon O, Gressin V, Speich R et al.: Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.170(11),1212–1217 (2004).
  MedlineGoogle Scholar
• 65  Degano B, Yaici A, Le Pavec J et al.: Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur. Respir. J.33(1),92–98 (2009).
  Medline CASGoogle Scholar
• 66  Galie N, Beghetti M, Gatzoulis MA et al.: Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation114(1),48–54 (2006).▪ This clinical trial reported the benefits of bosentan in congenital heart disease patients with pulmonary arterial hypertension.
  Medline CASGoogle Scholar
• 67  Gatzoulis MA, Beghetti M, Galiè N et al.: Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int. J. Cardiol.127(1),27–32 (2008).
  MedlineGoogle Scholar
• 68  Benza RL, Rayburn BK, Tallaj JA et al.: Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest129(4),1009–1015 (2006).
  Medline CASGoogle Scholar
• 69  Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L: Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur. Heart J.31(9),1124–1131 (2010).
  Medline CASGoogle Scholar
• 70  Kotlyar E, Sy R, Keogh AM et al.: Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease. Cardiol. Young16(03),268–274 (2006).
  MedlineGoogle Scholar
• 71  Hoeper MM, Seyfarth HJ, Hoeffken G et al.: Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur. Respir. J.30(6),1096–1102 (2007).
  Medline CASGoogle Scholar
• 72  Barst RJ, Mubarak KK, Machado RF et al.: Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br. J. Haematol.149(3),426–435 (2010).
  Medline CASGoogle Scholar
• 73  Minniti CP, Machado RF, Coles WA et al.: Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. Br. J. Haematol.147(5),737–743 (2009).
  Medline CASGoogle Scholar
• 74  Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J: Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur. Respir. J.26(5),858–863 (2005).
  Medline CASGoogle Scholar
• 75  Humbert M, Barst R, Robbins I et al.: Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J.24(3),353–359 (2004).
  Medline CASGoogle Scholar
• 76  Akagi S, Matsubara H, Miyaji K et al.: Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. Circ. J.72(7),1142–1146 (2008).
  Medline CASGoogle Scholar
• 77  Seyfarth H, Pankau H, Hammerschmidt S et al.: Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest.128(2),709–713 (2005).
  Medline CASGoogle Scholar
• 78  McLaughlin VV, Oudiz RJ, Frost A et al.: Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.174(11),1257–1263 (2006).
  Medline CASGoogle Scholar
• 79  Hoeper MM, Leuchte H, Halank M et al.: Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J.28(4),691–694 (2006).
  Medline CASGoogle Scholar
• 80  Hoeper M, Faulenbach C, Golpon H et al.: Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J.24(6),1007–1010 (2004).
  Medline CASGoogle Scholar
• 81  Mathai SC, Girgis RE, Fisher MR et al.: Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur. Respir. J.29(3),469–475 (2007).
  Medline CASGoogle Scholar
• 82  Galie N, Brundage BH, Ghofrani HA et al.: Tadalafil therapy for pulmonary arterial hypertension. Circulation119(22),2894–2903 (2009).
  Medline CASGoogle Scholar
• 83  McLaughlin VV, Benza RL, Rubin LJ et al.: Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J. Am. Coll. Cardiol.55(18),1915–1922 (2010).
  Medline CASGoogle Scholar
• 84  Wilkins MR, Paul GA, Strange JW et al.: Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med.171(11),1292–1297 (2005).
  MedlineGoogle Scholar
• 85  Barst RJ, Langleben D, Badesch D et al.: Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol.47(10),2049–2056 (2006).
  Medline CASGoogle Scholar
• 86  Benza RL, Barst RJ, Galie N et al.: Sitaxsentan for the treatment of pulmonary arterial hypertension. Chest134(4),775–782 (2008).
  MedlineGoogle Scholar
• 87  Langleben D, Cacoub P: A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. Eur. J. Clin. Invest.39,27–31 (2009).
  Medline CASGoogle Scholar
• 88  Roecker EB, Galie N, Olschewski H et al.: Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation117(23),3010 (2008).
  MedlineGoogle Scholar
• 89  D’Alonzo GE, Barst RJ, Ayres SM et al.: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med.115(5),343–349 (1991).▪ Widely referenced paper describing pulmonary arterial hypertension survival before targeted therapies became available.
  MedlineGoogle Scholar
• 90  Sandoval J, Bauerle O, Palomar A et al.: Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation89(4),1733 (1994).
  Medline CASGoogle Scholar
• 91  Benza RL, Miller DP, Gomberg-Maitland M et al.: Predicting survival in pulmonary arterial hypertension. Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation122,164–172 (2010).▪ Describes modern survival outcomes in a large cohort of pulmonary arterial hypertension patients.
  MedlineGoogle Scholar
• 92  Humbert M, Sitbon O, Chaouat A et al.: Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation122,156–163 (2010).
  MedlineGoogle Scholar
• 93  McLaughlin VV, Sitbon O, Badesch DB et al.: Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur. Respir. J.25(2),244–249 (2005).▪ Reports an improved survival with bosentan therapy in idiopathic pulmonary hypertension compared with the NIH-predicted survival.
  Medline CASGoogle Scholar
• 94  Denton C, Humbert M, Rubin L, Black C: Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann. Rheumat. Dis.65(10),1336–1340 (2006).
  Medline CASGoogle Scholar
• 95  McLaughlin VV: Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur. J. Clin. Invest.36(S3),10–15 (2006).
  Medline CASGoogle Scholar
• 96  Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM: Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J. Heart Lung Transplant.24(10),1626–1631 (2005).
  MedlineGoogle Scholar
• 97  Galiè N, Manes A, Negro L et al.: A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J.30(4),394–403 (2009).▪ Meta-analysis reporting an improved survival in the modern therapeutic era of pulmonary arterial hypertension management.
  MedlineGoogle Scholar
• 98  Sitbon O, McLaughlin VV, Badesch DB et al.: Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax60(12),1025–1030 (2005).
  Medline CASGoogle Scholar
• 99  Jacobs W, Boonstra A, Brand M et al.: Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era. J. Heart Lung Transplant.29(10),1150–1158 (2010).
  MedlineGoogle Scholar
• 100  Keogh A, McNeil K, Williams TJ et al.: The bosentan patient registry: long-term survival in pulmonary arterial hypertension. Int. Med. J. DOI: 10.1111/j.1445–5994. 2009.02139.x (2010) (Epub ahead of print).
  Google Scholar
• 101  Packer M, McMurray J, Massie BM et al.: Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J. Cardiac Fail.11(1),12–20 (2005).
  Medline CASGoogle Scholar
• 102  Packer M: Effects of the endothelin receptor antagonist bosentan on the morbidity and mortality in patients with chronic heart failure: results of the ENABLE 1 and 2 trial program. Presented at: American College of Cardiology 51st Annual Scientific Session. Atlanta, GA, USA 17–20 March 2002.
  Google Scholar
• 103  Kalra PR, Moon JCC, Coats AJS: Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int. J. Cardiol.85(2–3),195–197 (2002).
  MedlineGoogle Scholar
• 104  Teerlink JR: Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J. Cardiac Fail.8(3),124–127 (2002).
  MedlineGoogle Scholar
• 105  Kaluski E, Cotter G, Leitman M et al.: Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension; a multi-center randomized study. Cardiology109(4),273–280 (2008).
  Medline CASGoogle Scholar
• 106  Perez-Villa F, Cuppoletti A, Rossel V, Vallejos I, Roig E: Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension. Clin. Transplant.20(2),239–244 (2006).
  MedlineGoogle Scholar
• 107  Behr J, Ryu JH: Pulmonary hypertension in interstitial lung disease. Eur. Respir. J.31(6),1357–1367 (2008).
  Medline CASGoogle Scholar
• 108  Chaouat A, Naeije R, Weitzenblum E: Pulmonary hypertension in COPD. Eur. Respir. J.32(5),1371–1385 (2008).
  Medline CASGoogle Scholar
• 109  Stolz D, Rasch H, Linka A et al.: A randomised, controlled trial of bosentan in severe COPD. Eur. Respir. J.32(3),619–628 (2008).
  Medline CASGoogle Scholar
• 110  Valerio G, Bracciale P, Grazia D’Agostino A: Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther. Adv. Resp. Dis.3(1),15–21 (2009).
  MedlineGoogle Scholar
• 111  King TE, Behr J, Brown KK et al.: BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.177(1),75–81 (2008).
  Medline CASGoogle Scholar
• 112  Gunther A, Enke B, Markart P et al.: Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur. Respir. J.29(4),713–719 (2007).
  Medline CASGoogle Scholar
• 113  Seibold JR, Denton CP, Furst DE et al.: Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthrit. Rheumat.62(7),2101–2108 (2010).
  Medline CASGoogle Scholar
• 114  Lang I: Advances in understanding the pathogenesis of chronic thromboembolic pulmonary hypertension. Br. J. Haematol.149(4),478–483 (2010).
  Medline CASGoogle Scholar
• 115  Wittine LM, Auger WR: Chronic thromboembolic pulmonary hypertension. Curr. Treat. Options Cardiovasc. Med.12(2),131–141 (2010).
  MedlineGoogle Scholar
• 116  Pengo V, Lensing AW, Prins MH et al.: Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med.350(22),2257–2264 (2004).
  Medline CASGoogle Scholar
• 117  Becattini C, Agnelli G, Pesavento R et al.: Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest130(1),172–175 (2006).
  MedlineGoogle Scholar
• 118  Jamieson SW, Kapelanski DP, Sakakibara N et al.: Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann. Thorac. Surg.76(5),1457–1462; discussion 1462–1464 (2003).
  MedlineGoogle Scholar
• 119  Jaïs X, D’Armini AM, Jansa P et al.: Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension), a randomized, placebo-controlled trial. J. Am. Coll. Cardiol.52(25),2127–2134 (2008).▪ Important trial reporting the outcomes of bosentan use in chronic thromboembolic hypertension.
  Medline CASGoogle Scholar
• 120  Hughes R, Jais X, Bonderman D et al.: The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur. Respir. J.28(1),138–143 (2006).
  Medline CASGoogle Scholar
• 121  Becattini C, Manina G, Busti C, Gennarini S, Agnelli G: Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis. Thromb. Res.126(1),e51–e56 (2010).
  Medline CASGoogle Scholar
• 122  EMA: Tracleer: EPAR – Summary for the Public. EMA, London, UK (2009).
  Google Scholar
• 123  Benza RL, Barst RJ, Galie N et al.: Sitaxsentan for the treatment of pulmonary arterial hypertension. Chest134(4),775–782 (2008).
  MedlineGoogle Scholar
• 124  Mano Y, Usui T, Kamimura H: Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm. Drug Disposit.28(1),13–18 (2007).
  Medline CASGoogle Scholar
• 125  Barst RJ, Langleben D, Frost A et al.: Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.169(4),441–447 (2004).
  MedlineGoogle Scholar
• 126  Galie N, Olschewski H, Oudiz RJ et al.: Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation117(23),3010–3019 (2008).
  Medline CASGoogle Scholar
• 127  Oudiz RJ, Galiè N, Olschewski H et al.: Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.54(21),1971–1981 (2009).
  MedlineGoogle Scholar
• 128  Lavelle A, Sugrue R, Lawler G et al.: Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur. Respir. J.34(3),770–771 (2009).
  Medline CASGoogle Scholar
• 129  Hoeper MM, Olsson KM, Schneider A, Golpon H: Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy. Eur. Respir. J.33(6),1518–1519 (2009).
  Medline CASGoogle Scholar
• 130  Kenyon KW, Nappi JM: Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother.37(7),1055–1062 (2003).
  Medline CASGoogle Scholar
• 131  Highland KB, Strange C, Mazur J, Simpson KN: treatment of pulmonary arterial hypertension. Chest124(6),2087–2092 (2003).
  MedlineGoogle Scholar
• 132  Garin MC, Clark L, Chumney ECG, Simpson KN, Highland KB: Cost–utility of treatments for pulmonary arterial hypertension. Clin. Drug Invest.29(10),635–646 (2009).
  Medline CASGoogle Scholar
• 133  Wlodarczyk JH, Cleland LG, Keogh AM et al.: Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing. PharmacoEconomics24(9),903 (2006).
  MedlineGoogle Scholar
• 134  Stevenson MD, Macdonald FC, Langley J, Hunsche E, Akehurst R: The cost–effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III. Value Health12(8),1100–1105 (2009).
  MedlineGoogle Scholar
• 135  Chen Y, Jowett S, Barton P et al.: Clinical and cost–effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol. Assess.13(49),1–320 (2009).▪▪ Thorough evaluation of the cost–effectiveness of many pulmonary arterial hypertension monotherapies in the UK.
  MedlineGoogle Scholar
• 136  Rich S, Herskowitz A: Targeting pulmonary vascular disease to improve global health. Chest137(6 Suppl.),1S–5S (2010).
  MedlineGoogle Scholar
• 137  Barst R, McGoon M, Torbicki A et al.: Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.43(12 Suppl.),40–47 (2004).
  Google Scholar